Expression of Caveolin-1 in Normal and Pathological Human Pregnancy: A Narrative Review

Xiangnan Chen; Lihua Zhu; Linlin Chen; Fenghua Zhang; Hui Wang; Yanjun Yang; Wenfeng Ye

doi:10.23812/j.biol.regul.homeost.agents.20223603.53

Publication Frequency

Quarterly since 2025

Journal Articles

Search scope

Journal Center

Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

more

Volume Arrangement

2025

Vol 39, No 3 (2025)

Vol 39, No 2 (2025)

Vol 39, No 1 (2025)

Featured Articles

Macrophages in the pathogenesis of psoriasis and anti-psoriatic nanotherapies

Psoriasis is a common, chronic, and inflammatory skin disease. Macrophages account for about 61.3% of the inflammatory cells infiltrating psoriatic lesions. Modulating macrophage polarization, inhibiting their infiltration, and targeting the secretion of inflammatory factors and associated inflammatory pathways by these cells can alleviate psoriasis symptoms and inflammation. Moreover, nanomaterials as novel drug carriers, offer unique advantages such as large surface area, easy modification, high biocompatibility, good biodegradability, enhanced systemic adsorption, etc. Nanomaterials have great potential for efficient drug delivery and release, as well as improving therapeutic efficacy while reducing adverse effects. By systematically addressing the role of macrophages in psoriasis pathogenesis and the potential of nanomaterials in treating psoriasis through modulating macrophages, this review enhances our understanding of the disease mechanism and holds promise for novel therapeutic breakthroughs and advancements in the future treatment of psoriasis.

Expression of Caveolin-1 in Normal and Pathological Human Pregnancy: A Narrative Review

Xiangnan Chen, Lihua Zhu, Linlin Chen, Fenghua Zhang, Hui Wang, Yanjun Yang, Wenfeng Ye

Article ID: 6879
Vol 36, Issue 3, 2022

DOI: https://doi.org/10.23812/j.biol.regul.homeost.agents.20223603.53

Received: 9 July 2022; Accepted: 9 July 2022; Available online: 9 July 2022; Issue release: 9 July 2022

Abstract

Objective: The presence of caveolin-1(cav1) has been known for years. The aim of this narrative review was to investigate the expression of cav1 in normal and pathological pregnancy. Method: This review was carried out by two authors from the databases including PubMed and web of science. This review included all published studies about the role of cav1 in pregnancy-related diseases, including miscarriage of unknown cause, preeclampsia, gestational diabetes mellitus (GDM) and pregnancy in women with high body mass index (BMI). Results: The review showed that there were difference between the expression of cav1 of normal pregnancy and that of pathological pregnancy. The expression of cav1 is down-regulated in placenta of the group with unexplained spontaneous miscarriage in comparison with normal pregnancy. The level of cav1 in preeclampsia cases are lower than that of women in normal pregnancy. The expression of cav1 protein and mRNA in placenta of macrosomia induced by GDM was down-regulated and rats fed with HFHC had a decreased uterine expression of cav1 in the stage of labor. Conclusions: It can therefore be concluded that the caveolin-1 gene may be a potential susceptibility gene in pathological pregnancy.

Keywords

caveolin-1;caveolae;pregnancy

References

Supporting Agencies

This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Editor-in-Chief

Dr. Fabio Malavasi

Medical Genetics, University of Torino Medical School, Italy

Co-Editor-in-Chief

Prof. Marcello Iriti

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy

Indexing & Archiving

News & Announcements

2025-02-01

Notice of Change in Publication Schedule

In addition to the first issue that has already been published by the original publisher, there will be four more issues released this year, with scheduled publication dates in March, June, September, and December respectively.

2025-01-21

Notice: Ownership Transfer of the Journal

Starting from Volume 39 Issue 2 (2025), the ownership of Journal of Biological Regulators and Homeostatic Agents (ISSN: 0393-974X (P); 1724-6083 (O)) will be transferred from Biolife Sas to Asia Pacific Academy of Science Pte. Ltd. As of 21 January 2025, authors should make submissions to the new journal system and follow the author guidelines. Asia Pacific Academy of Science Pte. Ltd. will take over the publication of manuscripts being processed.

More Announcements...